FUJIFILM Diosynth Biotechnologies Signs 10-Year Manufacturing Agreement with Regeneron

• FUJIFILM Diosynth Biotechnologies has signed a $3 billion, 10-year contract manufacturing agreement with Regeneron Pharmaceuticals for US-based production.

• Manufacturing will be carried out at FUJIFILM’s new facility in Holly Springs, North Carolina, starting operations in 2025.

FUJIFILM Diosynth Biotechnologies, a global CDMO for biologics, vaccines, and advanced therapies, has announced a $3 billion manufacturing supply agreement with Regeneron Pharmaceuticals, Inc. The 10-year partnership will see FUJIFILM provide US-based production of Regeneron’s biologic medicines, beginning later this year at its facility in Holly Springs, North Carolina.

The Holly Springs site will serve as a cornerstone of FUJIFILM’s kojoX™ network, a modular manufacturing system designed to enable global standardisation and efficient technology transfer. The site is part of a broader $7 billion expansion effort across Europe and the United States.

“This agreement with an industry-leading biologic medicines company demonstrates that FUJIFILM Diosynth Biotechnologies is trusted by our partners to deliver through our technical expertise, talented team, and operational readiness,” said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio-CDMO Division, FUJIFILM Corporation, Japan.

FUJIFILM Diosynth Biotechnologies President and CEO Lars Petersen added, “We are delighted to be selected as the manufacturing supply partner for Regeneron, utilizing our new state-of-the-art facility in Holly Springs, North Carolina. The Holly Springs site is part of our kojoX™ interconnected manufacturing network, which provides a first-of-its-kind modular approach with standardized equipment, processes, and procedures across our sites around the globe to help ensure supply chain security and seamless tech transfers.”

“Partnering with Regeneron, a global leader in biotechnology and scientific innovation, is a true honour for us, as we bring together our exceptional teams and shared vision to make transformative medicine accessible to patients. We are honoured that Regeneron has the trust and confidence in our team’s ability to help deliver capacity faster, ensuring continuity of supply for patients in need,” he said.

Commenting on the partnership, Daniel Van Plew, executive vice president and general manager, Industrial Operations and Product Supply at Regeneron, stated, “At Regeneron, we have the privilege of making some of the best and most innovative therapeutics in the industry, and we are acutely aware of Regeneron’s impact on people’s lives as we work to help treat or even cure devastating diseases.”

He added, “We take our role seriously, and our decision to work with FUJIFILM Diosynth Biotechnologies reflects our belief that they will meet our high standards and grow with us. We are excited about this unique relationship, and we are already working to bring capacity online at FUJIFILM Diosynth Biotechnologies’ biologics manufacturing facility in Holly Springs, North Carolina.”

Iida further highlighted the strategic significance of the U.S. market and FUJIFILM’s ongoing investment: “As the U.S. is the largest market for biopharmaceuticals, FUJIFILM Corporation has made significant investments in the U.S. of about $4 billion in building world-class biopharmaceutical manufacturing sites, life sciences capabilities, and growing its technical talent.”

“Additionally, through our previously announced expansion efforts, we are pleased to share that we’ve already added 500 new positions as part of our overall goal of creating 1,400 new jobs in North Carolina by 2031,” he said.